Insmed Ends Brinsupri Development in HS Following Trial Setback

Insmed has discontinued development of Brinsupri (brensocatib) for hidradenitis suppurativa after disappointing mid-stage results. In the Phase IIb CEDAR trial, neither the 10 mg nor 40 mg dose outperformed placebo in reducing abscesses and inflammatory nodules, missing the primary endpoint. Reductions were 45.5% and 40.3% in the treatment arms versus 57.1% with placebo.

Secondary endpoints, including clinical response, flare frequency, symptom severity, and quality of life, were also not achieved. Detailed findings are expected at a future medical meeting. The drug was generally well tolerated, though a small number of patients experienced serious adverse events.

This setback follows a previous failure in chronic rhinosinusitis without nasal polyps. Despite this, Brinsupri’s outlook in bronchiectasis remains strong, with analysts expecting robust commercial performance. Meanwhile, the HS market continues to expand, driven by demand for more effective therapies.

08-04-2026